Abstract
Two multiple myeloma patients relapsed after autologous stem cell transplantation (ASCT). Conventional chemotherapy, including thalidomide, showed very little effect, but both patients responded well to a standard dose of bortezomib. One patient was treated with two additional cycles of bortezomib, but his clinical course suddenly deteriorated. Unrelated cord blood transplantation (CBT) with reduced-intensity conditioning regimen (RIC) was performed in refractory disease. After CBT, the clinical course was aggravated by tumor lysis syndrome and other conditions, thus resulting in patient death on day 34. Thereafter, we administered CBT with RIC on the second patient after just one course of bortezomib therapy since she was in partial remission. The second patient developed acute and chronic GVHD, and both responded to the steroid therapy. She has been in complete remission for more than 48 months after CBT. These results suggested that the timing of CBT with RIC may be very important, and cytoreduction with not only ASCT but also bortezomib could give a promising chance for a successful CBT.
Similar content being viewed by others
References
Barlogie B. Diagnosis and treatment of high-grade myeloma. Am J Med. 1990;88:445–6.
Tricot G, Vesole DH, Jagannath S, Hilton J, et al. Graft-versus-myeloma effect: proof of principle. Blood. 1996;87:1196–8.
Harris DT. In vitro and in vivo assessment of the graft-versus-leukemia activity of cord blood. Bone Marrow Transpl. 1995;15:17–23.
Howrey RP, Martin PL, Driscoll T, Szabolcs P, Kelly T, Shpall EJ, et al. Graft-versus-leukemia-induced complete remission following unrelated umbilical cord blood transplantation for acute leukemia. Bone Marrow Transpl. 2000;26:1251–4.
Kishi Y, Kami M, Miyakoshi S, et al. Early immune reaction after reduced-intensity cord-blood transplantation for adult patients. Transplantation. 2005;80:34–40.
Crawley C, Lalancette M, Szydlo R, et al. Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT. Blood. 2005;105:4532–9.
Lekakis L, Giralt S, Couriel D, et al. Phase II study of unrelated cord blood transplantation for adults with high-risk hematologic malignancies. Bone Marrow Transpl. 2006;38:421–6.
Yamada T, Tomonari A, Takahashi S, et al. Unrelated cord blood transplantation with a reduced-intensity conditioning regimen following autologous transplantation for multiple myeloma. Int J Hematol. 2004;80:377–80.
Miura Y, Azuma T, Kusumi E, et al. Graft-versus-myeloma effects in reduced-intensity cord blood transplantation. Int J Hematol. 2007;86:463–5.
Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003;348:2609–17.
Jagannath S, Barlogie B, Berenson J, et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol. 2004;127:165–72.
Acknowledgment
We thank Brian Quinn for language assistance.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Kasahara, I., Nishio, M., Yamamoto, S. et al. Cord blood transplantation with a reduced-intensity conditioning regimen for patients with relapsed aggressive multiple myeloma after cytoreduction with bortezomib. Int J Hematol 90, 413–415 (2009). https://doi.org/10.1007/s12185-009-0414-2
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12185-009-0414-2